Overview

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy in the frontline treatment of ovarian cancer in participants 70 years of age and older in routine clinical practice in Belgium. Bevacizumab will be used in combination with carboplatin/paclitaxel followed by bevacizumab as maintenance in accordance with the Summary of Product Characteristics (SmPC).
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Carboplatin
Paclitaxel